Sandesh Seth is Director at Actinium Pharmaceuticals, Inc. (ATNM). They have made 10 open-market trades across 2 companies since 2015, most recently 2025-08-18.
CIK 0001388320
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $148K since 2015, never a sale. Across 10 scored buys the stock is up 17.2% at ninety days, and 14.4 points ahead of the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 30% | 40% | 60% |
| Avg Move | +33.7% | -3.4% | +17.2% |
| Alpha | +24.9% | -2.1% | +14.4% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATNM | BUY | 2018-12-10 | 2018-12-10 | $0.44 | $4K | -10.2% | -0.1% | +25.0% |
| ATNM | BUY | 2018-07-17 | 2018-07-17 | $0.79 | $8K | -6.3% | -18.8% | -3.8% |
| ATNM | BUY | 2018-04-19 | 2018-04-20 | $0.38 | $2K | -5.7% | +0.8% | +103.2% |
| ATNM | BUY | 2017-08-02 | 2017-08-04 | $0.75 | $25K | -9.1% | -4.5% | -2.3% |
| ATNM | BUY | 2017-06-15 | 2017-06-15 | $1.16 | $9K | -0.8% | -10.2% | -46.4% |
| ATNM | BUY | 2016-12-30 | 2017-01-03 | $0.88 | $4K | +20.0% | +14.4% | +66.7% |
| ATNM | BUY | 2016-12-12 | 2016-12-12 | $0.98 | $5K | -4.9% | -3.0% | +42.6% |
| ATNM | BUY | 2016-04-14 | 2016-04-18 | $1.99 | $30K | -9.2% | -18.4% | -18.4% |
| RLMD | BUY | 2015-12-15 | 2015-12-17 | $3.19 | $30K | +181.7% | +2.9% | +2.9% |
| RLMD | BUY | 2015-12-14 | 2015-12-16 | $2.93 | $31K | +181.7% | +2.9% | +2.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.